Progesterone Antagonist Therapy in a Pelizaeus-Merzbacher Mouse Model  by Prukop, Thomas et al.
ARTICLE
Progesterone Antagonist Therapy
in a Pelizaeus-Merzbacher Mouse Model
Thomas Prukop,1,5 Dirk B. Epplen,1,5 Tobias Nientiedt,1 Sven P. Wichert,1,2 Robert Fledrich,1
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Pelizaeus-Merzbacher disease (PMD) is a severe hypomyelinating disease, characterized by ataxia, intellectual disability, epilepsy, and
premature death. In the majority of cases, PMD is caused by duplication of PLP1 that is expressed in myelinating oligodendrocytes.
Despite detailed knowledge of PLP1, there is presently no curative therapy for PMD. We used a Plp1 transgenic PMD mouse model to
test the therapeutic effect of Lonaprisan, an antagonist of the nuclear progesterone receptor, in lowering Plp1 mRNA overexpression.
We applied placebo-controlled Lonaprisan therapy to PMD mice for 10 weeks and performed the grid slip analysis to assess the clinical
phenotype. Additionally, mRNA expression and protein accumulation as well as histological analysis of the central nervous systemwere
performed. Although Plp1mRNA levels are increased 1.8-fold in PMDmice compared to wild-type controls, daily Lonaprisan treatment
reduced overexpression at the RNA level to about 1.5-fold, whichwas sufficient to significantly improve the poormotor phenotype. Elec-
tron microscopy confirmed a 25% increase in the number of myelinated axons in the corticospinal tract when compared to untreated
PMD mice. Microarray analysis revealed the upregulation of proapoptotic genes in PMD mice that could be partially rescued by Lonap-
risan treatment, which also reduced microgliosis, astrogliosis, and lymphocyte infiltration.Introduction
Most individuals affected by Pelizaeus-Merzbacher disease
(PMD [MIM 312080]) show a severe and progressive leuko-
dystrophy of early onset. Infants develop nystagmus, poor
head control, cerebellar dysfunction, spasticity of upper
and lower extremities, and cognitive impairment.1–5 Onset
and progression of PMD is clinically variable, however, and
depends on the specific PLP1 mutation and, based on
insight from bona fide PMD mouse models, on unknown
modifier genes.6,7 Despite the detailed knowledge that
has accumulated on the molecular genetic basis of the
PMD,4,8 there is no curative therapy available.
Both proteolipid protein (PLP) and its smaller splice iso-
form DM20 are tetraspan membrane proteins in com-
pacted myelin that account for nearly 20% of the total
CNS myelin proteome.9 Mutations or dosage alterations
of X-linked PLP1 cause PMD and spastic paraplegia type
2 (SPG2 [MIM 312920]) in human and clinically similar
phenotypes in rodent models of PMD. Dysmyelination,
secondary inflammation, and axonal damage contribute
to severe motor impairment.4,5,10–13 The most common
cause of PMD, accounting for approximately 60% of all
cases, is duplication of entire PLP.8,14,15
It is thought that both Plp1 overexpression and point
mutations in the gene exert a toxic gain-of-function effect
in oligodendrocytes that is considerably more severe than
Plp1 loss-of-function resulting from null mutations.5,16–21
In fact, gene deletions or other null mutations4,22 underlie
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The Amdegenerative changes of long axonal tracts.23–25 The ability
of proteolipids to bind cholesterol is important for
myelination,26 but the stoichiometry of PLP1 and choles-
terol appears critical. In mice with Plp1 overexpression,
PLP1/DM20 (lacking equivalent amounts of cholesterol)
accumulates in the endo/lysosomal compartment.19,27
Indeed, treatment of these Plp1-overexpressing mice with
dietary cholesterol dramatically ameliorates the mutant
phenotype.28
Several Plp1 transgenic PMD models, defined by extra
copies of wild-type Plp1, have been generated that exhibit
a range of phenotypes, depending on gene dosage.29–33 In
the present study, we used Plp1 transgenic homozygous
mice in line #72, as described by Readhead et al.30
(referred to hereafter as PMD mice). In the CNS, the
elevated Plp1 expression level causes dys- and demyelin-
ation, oligodendrocyte death, axonal loss in long fiber
tracts, and microgliosis with lymphocyte infiltration. We
note that transgenic mouse line #72 used here models
the comparatively milder forms of PMD or SPG2,
whereas line #66 models the severely affected ‘‘classical’’
PMD.21,28,30,32,34–36
Ligand-controlled transcription factors, such as the nu-
clear progesterone receptor, are promising targets for the
therapy of myelin diseases caused by myelin gene overex-
pression.37 In the peripheral nervous system (PNS), proges-
terone promotes the synthesis of at least two myelin
proteins, MPZ and PMP22, possibly by stimulating accu-
mulation of two other transcription factors, EGR2 and
SOX-10, in Schwann cells.38–43 For the CNS, there is onlye, 37075 Go¨ttingen, Germany; 2Department of Psychiatry and Psychother-
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indirect evidence that progesterone serves a similar role as
a ‘‘promyelinating’’ factor. In cultures of primary oligoden-
drocytes and organotypic slice cultures of cerebellum,
progesterone increases the accumulation of MBP and
20,30-cyclic nucleotide 30 phosphodiesterase (CNPase).44,45
Moreover, progesterone positively modulates remyelina-
tion after toxin-induced lesions of the cerebellar peduncle
in aging rats.46 Additionally, progesterone contributes to
oligodendrocyte precursor cell proliferation and differenti-
ation.47,48 More recently, in a spinal injury model49 and in
a Cuprizone model of demyelination,50 progesterone
increased Plp1 mRNA expression. These observations pro-
vide proof of principle that the nuclear progesterone recep-
tor acts upstream of Plp1 transcription in vivo and is
therefore a plausible target to pharmacologically lower
Plp1 expression in diseases such as PMD.
The present study aimed at testing the potential thera-
peutic effect of a newly developed progesterone antago-
nist, Lonaprisan (ZK230211), in a transgenic mouse model
of PMD. We hypothesized that antagonists of steroid hor-
mones can lower total Plp1 transcription in oligodendro-
cytes (and thus correct abnormal Plp1 mRNA and protein
levels). This approach could lead to a rational therapy for
the most common subgroup of PMD caused by PLP1
duplications.Material and Methods
All experiments were conducted according to the Lower Saxony
State regulations for animal experimentation in Germany, and
animal studies were approved by the appropriate authority.
Transgenic Mice
Male mice in line #72 homozygous for an autosomal murine Plp1
transgene30 and maintained on the C57BL/6 background were
used as bona fide models for human PMD. Plp1 overexpression
was 1.8-fold (see Results) and motor symptoms in PMD mice
were alreadymeasurable at study start at 3 weeks of age. Generally,
untreated homozygous #72 mice fail to survive beyond 6 months
of age.
Antiprogesterone Treatment
Lonaprisan (ZK230211), a nuclear progesterone antagonist, was
kindly provided by Bayer.51 Male mice were assigned to treatment
arms at random with respect to phenotype, weight, and parents.
Lonaprisan or vehicle was administered by daily subcutaneous
injections. Lonaprisan was dosed at 125 mg/kg body weight and
suspended in a mixture of 90% sesame oil and 10% benzylben-
zoate. In one control group, wild-type mice received vehicle
without Lonaprisan. Treatment started at 3 weeks of age (time of
weaning) and was performed for 10 weeks.
Brain Level Analysis of Lonaprisan
To examine the blood-brain-barrier passage of Lonaprisan, male
wild-type mice were treated with Lonaprisan at 125 gm/kg body
weight by subcutaneous injections on a daily basis for 10 days.
At 1, 3, 9, and 24 hr after the last dose, the mice were sacrificed
and perfused with HBSS in order to avoid interference with intra-534 The American Journal of Human Genetics 94, 533–546, April 3, 2vasal Lonaprisan, and brains were isolated. Lonaprisan levels were
measured by mass spectrometry at Bayer.
Phenotype Analyses
Phenotypic analyses were performed by the same investigator
blinded to genotype and therapy group. Motor phenotype was
assessed by a limb-slipping test (grid test) in which mice
were placed on a metal grid with 1 cm spacing between bars
(bar diameter: 3 mm). Over a total walking distance of 2 m,
the number of slips of both hindlimbs and forelimbs were
assessed by the examiner. Disease severity was independently
assessed with a clinical ranking scale from 1 to 5, with the
following criteria: 1, normal phenotype (healthy); 2, ataxic gait;
3, tremor; 4, seizures; 5, death. Phenotype analyses were carried
out at 3, 7, 10, and 13 weeks of age. Body weight was continu-
ously recorded.
Histologic Analyses
Cervical spinal cord and total brain was fixed by immersion in 4%
paraformaldehyde and 2.5% glutaraldehyde in cacodylate buffer
(pH 7.2) for electron microscopy (EM) or in 4% paraformaldehyde
for immunohistochemistry (IHC).
For IHC analyses, diaminobenzidine (DAB) stainings were
used and the antibodies were diluted to the following concentra-
tions: OLIG-2 (Dana-Farber Cancer Institute, rabbit polyclonal)
1:200; GFAP (Novocastra, murine monoclonal) 1:200; MAC-3
(PharMingen, rat monoclonal) 1:400; CD3 (Serotec, rat mono-
clonal) 1:150; BAX (Santa Cruz, mouse monoclonal) 1:100;
Ki67 (DakoCytomation) 1:100; c-MYC (Santa Cruz, mouse mono-
clonal) 1:100. Immunostained cells were quantified in the cortico-
spinal tract (CST, at cervical vertebral body 5) and in the ventral
corpus callosus (CC).
For EM analyses, epoxy resin (Serva) embedding was performed
after fixation in 1% OsO4.
52 Ultrathin sections were contrasted by
uranylacetate and lead citrate. Myelinated and unmyelinated
axons were counted in the CST.
RNA Expression Analyses
RNA from total brain was isolated at study end from 13-week-old
mice according to the manufacturer’s instructions (RNeasy lipid
tissue minikit; QIAGEN) with TRIzol reagent (Invitrogen). Real-
time quantitative PCR reactions (Taqman and SYBR Green assay)
were carried out with the Lightcycler 480 (Roche). Samples ran
in triplicate, each within 10 ml total volume according to a two-
step protocol. Quantitation of PCR product was performed with
the comparative DDCt method as recommended by the manufac-
turer. Transgenic Plp1 mRNA overexpression was normalized
against Ppia mRNA. For quantification of Lonaprisan effect on
Plp1 expression, normalization was performed against the non-
steroid-regulated, non-myelin-related, and ubiquitously expressed
exon 1B transcript of Pmp22.39,53,54,55 Bax, Jun, and Casp7 mRNA
expression was normalized against the mean of Rplp0, Ppia,
and Atp5b mRNA expression. Primer sequences can be provided
upon request.
Microarray Analysis
Total brain mRNA was taken from each three individual placebo-
(n ¼ 3) and Lonaprisan- (n ¼ 3) treated PMD mice. Mouse Gene
1.0 ST tiling arrays (Affymetrix) were used for the measurements.
Data analyses were performed by the integrated software packages
Genomics Suite (Partek). The Gene Set Enrichment Analysis014
Figure 1. Pilot Studies in PMD Mice
(A) A short-term dosage study over 10 days
and a long-term therapy study over 10
weeks were performed.
(B) Lonaprisan crossed the blood-brain bar-
rier and was detectable 24 hr after the last
subcutaneous dose.
(C) Plp1 mRNA expression was increased
1.8-fold when compared to wild-type
controls.
(D) Dose-response curve demonstrating
downregulation of Plp1mRNA overexpres-
sion in a short-term pilot study.
ns indicates not significant, *p < 0.05,
***p < 0.001, shown mean 5 SEM.(GSEA) software was used to identify coordinated changes in a
priori defined sets of functionally grouped genes.56,57
Sample Size Considerations
Sample sizes were calculated a priori for PMD mice by G*Power
software taking an alpha error of 5% and a power (1 – beta error)
of 80% into account. Effect sizes and standard deviations were
prespecified as follows: d ¼ 1.2 and SD ¼ 15% for the reduction
of Plp1 mRNA fold-expression, d ¼ 1.8 and SD ¼ 10% for the
preservation of myelinated axons/area, and d ¼ 1.1 and SD ¼
20% for the reduction of number of slips.
Statistical Analysis
All values are expressed as mean 5 SEM. We have tested all our
data on Gaussian distribution and used parametric (Student’s
t test) or nonparametric (Mann-Whitney U-test) testing, where
applicable. Correlation analyses were performed by the Spear-
man’s rank correlation test. Statistica 7.0 (StatSoft) was used for
statistical analyses.Results
Lonaprisan Crosses the Blood-Brain Barrier and
Downregulates Plp1 Overexpression
A pilot study was performed to examine whether Lonapri-
san crosses the blood-brain barrier (Figure 1A). Lonaprisan
levels were determined by mass spectroscopy in total
brain lysates from wild-type mice, prepared 1, 3, 9, and
24 hr after the last subcutaneous application. Drug levels
were detectable at 1 hr, increased up to 9 hr after the
last dose, and were still detectable after 24 hr (1 hr:
mean ¼ 4.8 mmol/l, SEM ¼ 1.6; 3 hr: mean ¼ 5.6 mmol/l,
SEM ¼ 2.6; 9 hr: 10.8 mmol/l, SEM ¼ 4.9; 24 hr: mean ¼
0.8 mmol/l, SEM ¼ 0.2) (Figure 1B). In an attempt to estab-
lish the optimal dosage for Plp1 downregulation, we
treated PMD mice over 10 days at three different dosagesThe American Journal of Humaand examined Plp1 mRNA expres-
sion 24 hr after the last injection.
Placebo-treated PMD mice showed a
significant 1.8-fold Plp1 overexpres-
sion (n ¼ 12, mean ¼ 1.8, SEM ¼
0.1) compared to wild-type controls
(n ¼ 15, mean ¼ 1.0, SEM ¼ 0.04,
p < 0.001) (Figure 1C). Lonaprisan dosages of 2 mg/kg
(n ¼ 8, mean ¼ 1.9, SEM ¼ 0.1) and 20 mg/kg (n ¼ 8,
mean ¼ 1.7, SEM ¼ 0.1) were not sufficient to reduce the
Plp1 mRNA overexpression in PMD mice (n ¼ 8, mean ¼
1.8, SEM ¼ 0.1) after short-term treatment. However,
Lonaprisan treatment in PMD mice at the dosage of
125 mg/kg significantly reduced Plp1 mRNA to 1.5-fold
expression (n ¼ 8, mean ¼ 1.5, SEM ¼ 0.1, p < 0.05)
when compared to placebo-treated PMD mice (Figure 1D).
This decrease is similar in extent to the therapeutic effect
of a progesterone antagonist (Onapristone) in a transgenic
rat model of CMT1A.37
Lonaprisan Long-Term Treatment Ameliorates the
Clinical Phenotype of PMD Mice
After identifying the optimal dosage for Plp1mRNA down-
regulation, Lonaprisan was subcutaneously applied to
3-week-old PMDmice for 10 consecutive weeks by daily in-
jections at the dosage of 125 mg/kg, and placebo-treated
wild-type and PMD mice served as controls (Figure 1A).
Again, 10 weeks of Lonaprisan treatment reduced Plp1
overexpression at the mRNA level to 1.6-fold expression
(n ¼ 11, mean overexpression level ¼ 1.6-fold, SEM ¼
0.1, p < 0.01) when compared to PMD controls (n ¼ 12,
mean overexpression level ¼ 1.8-fold, SEM ¼ 0.1) (Fig-
ure 2A), confirming data from the pilot experiments
(Figure 1D).
Three-week-old PMDmice showed minor but significant
motor deficiencies (i.e., more slips in the grid test) at the
beginning of the trial (n ¼ 12, mean ¼ 9.0 slips, SEM ¼
0.6, p < 0.05) compared to wild-type controls (n ¼ 30,
mean ¼ 6.9, SEM ¼ 0.4), but there was no difference
compared to PMDmice in the Lonaprisan treatment group
(n ¼ 11, mean ¼ 8.4, SEM ¼ 0.6) (Figures 2B and 2C). This
confirmed a balanced stratification between the placebon Genetics 94, 533–546, April 3, 2014 535
Figure 2. Behavioral Analysis of PMD Mice after Lonaprisan Therapy
(A) Lonaprisan long-term treatment downregulated Plp1 mRNA overexpression.
(B) Regular grid test analyses counting the number of slips were performed at the beginning at 3 weeks of age, at 7 and 10 weeks, and
finally at the end at 13 weeks of age.
(legend continued on next page)
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and Lonaprisan PMD mice at therapy start. Seven weeks
later, PMD groups had deteriorated in motor performance
as expected. Moreover, Lonaprisan treatment (n ¼ 11,
mean ¼ 10.7 slips, SEM ¼ 0.9) did not reveal a significant
difference in motor deficiencies in comparison to the per-
formance of PMD mice receiving placebo (n ¼ 12, mean ¼
12.8 slips, SEM ¼ 1.1, not significant), although a clear
trend was noticed (Figure 2C). However, after 10 weeks of
Lonaprisan therapy, PMD mice showed significantly less
progression (n ¼ 11, mean ¼ 12.4 slips, SEM ¼ 0.6, p <
0.01) compared to placebo-treated PMD mice (n ¼ 12,
mean ¼ 15.3 slips, SEM ¼ 0.7) (Figure 2C), although the
difference to wild-type mice remained obvious (n ¼ 30,
mean¼ 8.6 slips, SEM¼ 0.5) as shown in Figure 2D. Impor-
tantly, these grid test results could be directly correlated to
the level of Plp1 mRNA overexpression in total brain (r2 ¼
0.2676, p < 0.05), strongly suggesting a direct Plp1-dosage
effect on the motor phenotype (Figure 2E).
Finally, we applied a clinical score at the end of the trial
in order to independently quantify Lonaprisan’s therapeu-
tic effect. Here, Lonaprisan treatment increased the per-
centage of PMD mice with a low score of 2 (ataxic gait)
or less (n ¼ 11, 91%) when compared to placebo-treated
PMDmice (n¼ 12, 58%). Wild-type controls always scored
1.0 (n ¼ 30) (Figure 2F).
Body weight recordings revealed a significant body
weight loss already present in 3-week-old PMD mice (n ¼
12, mean ¼ 9.7 g, SEM ¼ 0.2) compared to wild-type situ-
ation (n ¼ 30, mean ¼ 11.1 g, SEM ¼ 0.2, p < 0.001). This
difference remained present throughout the study at the
ages of 7 (mean ¼ 21.3 g, SEM ¼ 0.8 and mean ¼ 23.7 g,
SEM ¼ 0.3, p < 0.01), 10 (mean ¼ 25.3 g, SEM ¼ 0.5 and
mean ¼ 28.1 g, SEM ¼ 0.3, p < 0.001), and 13 (mean ¼
27.8 g, SEM ¼ 0.5 and mean ¼ 30.4 g, SEM ¼ 0.3, p <
0.001) weeks (Figure 2G). In contrast, PMD placebo con-
trols and Lonaprisan-treated PMD mice did not show any
body weight differences at study start (n ¼ 11, mean ¼
10.2 g, SEM ¼ 0.5). Also, Lonaprisan therapy in PMD
mice did not alter the body weight in 7- (mean ¼ 21.5 g,
SEM ¼ 0.6), 10- (mean ¼ 24.7 g, SEM ¼ 0.6), and 13-
(mean ¼ 26.8 g, SEM ¼ 0.6) week-old mice at the study
end (Figures 2G and 2H).
Preservation of Myelinated Axons
To investigate the therapeutic effect of Lonaprisan on dys-
myelination and histopathology in the central nervous(C and D) Differences between Lonaprisan-treated PMDmice (n ¼ 11
increased with age and became significant at 13 weeks of age at stud
time point. Wild-type values (n ¼ 30) are depicted for comparison (o
(E) Plp1 mRNA expression correlated with the grid test analysis, str
phenotype.
(F) By applying a clinical score in a descriptive analysis, PMD mice s
centage of mice showing solely ataxic gait or even healthy condition
(G and H) A significant body weight loss was already present in 3-w
(n ¼ 30). This difference remained present throughout the study. In
(n ¼ 11) did not show any body weight differences at study start and
ns indicates not significant, *p < 0.05, **p < 0.01, ***p < 0.001, sho
The Amsystem, we examined a region that is severely affected in
PMD mice (Figure 3A). The corticospinal tract (CST) of
the cervical spinal cord was used for electron microscopy
(EM) and morphometry. Whereas wild-type mice dis-
played on average 838 myelinated axons per 1,000 mm2
cross sectional area in the CST (n ¼ 3, SEM ¼ 49.6), PMD
mice with severe dysmyelination showed only 198myelin-
ated axons per 1,000 mm2 (n ¼ 10, SEM ¼ 48.7, p < 0.001)
(Figure 3A, quantification in 3B). Importantly, as judged by
EM, the 10 week Lonaprisan therapy increased the number
of myelinated axons by 25% to 254 in PMD mice (n ¼ 11,
SEM¼ 52.1, p< 0.05) (Figure 3B). Correspondingly, unmy-
elinated CST axons were numerous in PMD mice (n ¼ 5,
mean ¼ 489/1,000 mm2, SEM ¼ 91.6) but rare in wild-
type mice (n ¼ 3, mean ¼ 7/1,000 mm2, SEM ¼ 2.0, p <
0.01). However, Lonaprisan treatment did not alter the
number of unmyelinated axons in PMD mice (n ¼ 5,
mean ¼ 524/1,000 mm2, SEM ¼ 77.6) (Figure 3C).
As expected, g-ratio analysis also revealed a significant
hypomyelination in PMD mice (n ¼ 5, mean ¼ 0.97,
SEM ¼ 0.01) compared to wild-type controls (n ¼ 3,
mean ¼ 0.84, SEM ¼ 0.01, p < 0.001). Again, Lonaprisan
therapy over 10 weeks did not influence the extent of
hypomyelination in PMD mice (n ¼ 5, mean ¼ 0.97,
SEM ¼ 0.01, not significant) (Figure 3D). The g-ratio distri-
bution as a function of axon size was also not different
between placebo- and Lonaprisan-treated PMD mice (Fig-
ure 3E). When combined with the results above, we
conclude that Lonaprisan acts on axonal preservation
without any effects on myelination.
Correlation of Plp1 mRNA Expression, Myelinated
Axons, and Phenotype
Plp1 mRNA expression levels correlated with the motor
phenotype as measured by the grid test analysis in treated
and untreated PMD mice (Figure 2E). Histological analysis
showed that the number of myelinated axons correlated
inversely with the Plp1 mRNA expression (r2 ¼ 0.3693,
p < 0.01) (Figure 3F), suggesting that Plp1 overexpression
in oligodendrocytes (and abnormal gain of function)
leads to the loss of myelinated axons. Likewise, the num-
ber of myelinated axons in the CST correlated with the
motor phenotype (r2 ¼ 0.2729, p < 0.05) (Figure 3G),
demonstrating a strong link between Plp1 dosage, num-
ber of myelinated axons, and clinical phenotype in
PMD mice.) (filled squares) and placebo-treated control mice (n ¼ 12) (circles)
y end (C), which is illustrated in higher magnification of the final
pen bar) (D).
ongly suggesting a direct effect of Plp1 expression on the motor
howed a pathologic phenotype and Lonaprisan increased the per-
.
eek-old PMD mice (n ¼ 12) compared to the wild-type situation
contrast, PMD placebo controls and Lonaprisan-treated PMD mice
Lonaprisan therapy did not alter the body weight by study end.
wn mean5 SEM.
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Figure 3. Electron Microscopic Analyses
of the CNS after Lonaprisan Therapy in
PMD Mice
(A) Electron microscopic graphs of the
corticospinal tract showed preservation
of myelinated axons after Lonaprisan
treatment.
(B) Myelinated axons are reduced in PMD
mice compared to wild-type controls,
and after Lonaprisan therapy myelinated
axons are increased.
(C) Nonmyelinated axon number was
increased in the disease situation but was
unaltered by Lonaprisan treatment.
(D and E) In PMD mice, Lonaprisan ther-
apy did not increase the mean myelin
sheath thickness (D) and corresponding
myelin sheath thickness according to
axonal size (E).
(F and G) Plp1 mRNA expression levels
correlated to the myelinated axon number
(F), and myelinated axon number corre-
lated to the phenotype (G).
Scale bars represent 1.7 mm. CST indicates
corticospinal tract, ns indicates not sig-
nificant, *p < 0.05, ***p < 0.001, shown
mean5 SEM.Lonaprisan Therapy Modifies Expression of
Apoptosis-Related Genes
To assess the molecular consequences of Lonaprisan treat-
ment, we performed individual microarray analyses on
brain cDNA preparations obtained from PMDmice treated
with placebo (n ¼ 3) and Lonaprisan (n ¼ 3). When
searching for functional groups, gene set enrichment
analysis (GSEA) revealed a significant downregulation of
genes involved in apoptosis in mouse brains after Lonap-
risan therapy (p < 0.001, enrichment score ¼ 0.38)
(Figure 4A). The heatmap plot for apoptosis visualized538 The American Journal of Human Genetics 94, 533–546, April 3, 201462 genes involved in the apoptosis
pathway (Figure 4B). In order to
validate the microarray data, we
performed quantitative RT-PCR ana-
lyses on total brain cDNAs obtained
from individual wild-type controls
and PMD mice, treated either with
placebo or Lonaprisan. For example,
Bax mRNA expression was signifi-
cantly increased in PMD mice (n ¼
7, mean ¼ 2.2-fold, SEM ¼ 0.3)
compared to wild-type controls (n ¼
8, defined as 1.0, SEM ¼ 0.2, p <
0.01). Here, Lonaprisan treatment
significantly downregulated Bax
overexpression when compared to
placebo-treated PMD mice (n ¼ 11,
mean ¼ 1.1-fold, SEM ¼ 0.1, p <
0.001), reaching wild-type levels
(Figure 4D). Jun mRNA expression
was also increased in PMD mice(n ¼ 7, mean ¼ 4.2-fold, SEM ¼ 0.7) compared to wild-
type controls (n ¼ 8, defined as 1.0, SEM ¼ 0.5, p <
0.01) and Lonaprisan therapy normalized the mRNA
overexpression to 1.3-fold (n ¼ 11, mean ¼ SEM ¼ 0.3,
p < 0.001), again approaching wild-type levels (Fig-
ure 4C). Finally, we measured Casp7 mRNA levels that
were upregulated in PMD mice (n ¼ 11, mean ¼ 2.6-
fold, SEM ¼ 0.3) compared to wild-type controls (n ¼ 8,
defined as 1.0, SEM ¼ 0.2, p < 0.001). Lonaprisan
treatment over 10 weeks downregulated Casp7 overex-
pression in PMD mice to 1.6-fold (n ¼ 11, SEM ¼ 0.2,
Figure 4. Microarray Analysis in PMD Mice Treated with Lonaprisan
(A and B) Microarray analysis revealed a downregulation of genes involved in apoptosis after Lonaprisan therapy (core enriched genes
in bold).
(C–E) Jun, Casp7, and Bax were validated by quantitative RT-PCR.
*p < 0.05, **p < 0.01, ***p < 0.001, shown mean5 SEM.p < 0.05), but without reaching wild-type levels (p > 0.05)
(Figure 4E).
Oligodendrocyte Loss, Microgliosis, and Infiltration of
Lymphocytes
Next, we performed immunohistochemistry in the CST
and corpus callosum (CC) in order to validate the effect
of Lonaprisan treatment on the selected histopathological
marker proteins OLIG-2, MAC-3, GFAP, and CD3 (Fig-
ure 5A). Counting OLIG-2-positive cells in the CST
demonstrated more than 50% decrease of oligodendro-
cyte density in PMD mice (n ¼ 6, mean ¼ 7 cells per
30,000 mm2, SEM ¼ 0.7, p < 0.001) when compared
to wild-type controls (n ¼ 3, mean ¼ 16 cells per
30,000 mm2, SEM ¼ 0.6). Here, 10 weeks of Lonaprisan
treatment significantly prevented oligodendrocyte lossThe Am(n ¼ 6, mean ¼ 11 cells per 30,000 mm2, SEM ¼ 1.4, p <
0.05), although wild-type values were not reached
(Figure 5B). As expected, wild-type brains showed only a
few microglia/macrophages within the CST as indicated
by MAC-3-positive cells counts (n ¼ 3, mean ¼ 5 cells
per 30,000 mm2, SEM¼ 1.2). In PMDmice, MAC-3-positive
cells were several-fold increased, indicating active micro-
gliosis (n ¼ 6, mean ¼ 92 cells per 30,000 mm2, SEM ¼
15.2, p < 0.01). Lonaprisan-treated PMD mice displayed
fewer MAC-3-positive microglia and macrophages com-
pared to untreated PMD mice (n ¼ 6, mean ¼ 31 cells
per 30,000 mm2, SEM ¼ 4.2, p < 0.01) but without ap-
proaching wild-type values (Figure 5C). Finally, GFAP cell
counts in the CST revealed that Lonaprisan treatment
also reduced astrogliosis (n ¼ 6, mean ¼ 8 cells per
30,000 mm2, SEM ¼ 0.8) when compared to untreatederican Journal of Human Genetics 94, 533–546, April 3, 2014 539
Figure 5. Immunohistochemistry in CNS after Treatment with Lonaprisan in PMD Mice
(A) Immunohistochemistry showing OLIG-2-, MAC-3-, GFAP-, and CD3-positive cells in wild-type and placebo- and Lonaprisan-treated
PMD mice.
(B–E) Lonaprisan therapy reduced oligodendrocyte loss (B), microgliosis (C), astrogliosis (D), and lymphocyte infiltration (E).
(legend continued on next page)
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PMD mice (n ¼ 6, mean ¼ 11 cells per 30,000 mm2, SEM ¼
1.1, p< 0.05). Moreover, wild-type values were not reached
(n ¼ 3, mean ¼ 5 cells per 30,000 mm2, SEM ¼ 1.5)
(Figure 5D). In the CSTarea of wild-type mice, we never de-
tected CD3-positive lymphocytes (n ¼ 3, mean ¼ 0 cells
per 30,000 mm2, SEM ¼ 0). However, we detected CD3-
positive T cells in untreated PMD mice, suggesting that
lymphocyte infiltration is stimulated by the disease
(n ¼ 6, mean ¼ 3 cells per 30,000 mm2, SEM ¼ 0.8, p <
0.05). In the Lonaprisan treatment group, the number
of CD3-positive cells was significantly reduced (n ¼ 6,
mean ¼ 0.7 cells per 30,000 mm2, SEM ¼ 0.3, p< 0.05), sta-
tistically approaching the values found in wild-type mice
(Figure 5E).
Additionally, sections were analyzed for the expression
of c-MYC (cell cycle regulator), Ki67 (proliferation marker),
and BAX (apoptosis related marker). The density of c-MYC-
positive cells in the CST (n ¼ 6, mean ¼ 119 cells per sec-
tion, SEM ¼ 9.5) was not different from wild-type controls
(n ¼ 3, mean 110 cells per section, SEM ¼ 17.9). However,
Lonaprisan therapy reduced this number to less than 50%
in the CSTof PMDmice (n¼ 6,mean¼ 41 cells per section,
SEM ¼ 19.4, p < 0.01) (Figure 5F). Further, Ki67-positive
cells were found in significantly higher density in the
CST of PMD mice (n ¼ 6, mean ¼ 14 cells per section,
SEM ¼ 2.3, p < 0.01) than in wild-type controls (n ¼ 3,
mean ¼ 3 cells per section, SEM ¼ 1.2). Ten weeks of
Lonaprisan therapy reduced the density of Ki67-positive
cells by more than 60% (n ¼ 5, mean ¼ 5 cells per section,
SEM ¼ 1.3, p < 0.05) without reaching wild-type values
(Figure 5G). Interestingly and in line with transcriptional
data (Figure 4D), the density of cells expressing the
apoptosis-associated protein BAX in the corpus callosum
was increased in PMD mice (n ¼ 4, mean ¼ 2.5 cells per
30,000 mm2, SEM ¼ 0.5, p < 0.001) when compared to
wild-type mice (n ¼ 5, mean ¼ 0.2 cells per 30,000 mm2,
SEM ¼ 0.1) and reduced after Lonaprisan therapy (n ¼ 3,
mean ¼ 0.8 cells per 30,000 mm2, SEM ¼ 0.3, p < 0.05)
(Figure 5H).Discussion
We tested the hypothesis that lowering toxic Plp1 overex-
pression in oligodendrocytes in a transgenic animal model
of PMD via steroid antagonist would enable oligodendro-
cytes to better support axons. This may lead to a translat-
able therapy for a subgroup of individuals affected by
PMD caused by PLP1 duplications.
A number of factors regulating Plp1 transcription in
oligodendrocytes have been identified in vitro, such as
MyT1,58 microRNA miR-20a,59 and the zinc finger protein(F–H) Further, cells positive for c-MYC, Ki67, and BAX were reduced a
resulting in reduced proliferation and apoptosis in PMD mice.
Scale bars represent 10 mm. CST indicates corticospinal tract, CC indic
0.01, ***p < 0.001, shown mean5 SEM.
The AmYY1.60 Moreover, several potential transcription factor
binding sites and enhancer elements have been identified
in the 50-flanking sequence61–63 and within intron 1 of
mouse Plp1 (AP-1).64,65 One widely expressed transcription
factor that is present in oligodendrocytes66 and can be
pharmacologically targeted is the nuclear progesterone re-
ceptor, a ligand-activated Zinc-finger protein that is regu-
lated by progesterone and inhibited by specific synthetic
antagonists. The nuclear progesterone receptor is a mem-
ber of amuch larger steroid receptor superfamily that binds
to palindromic response elements in the promoter regions
of steroid-responsive genes.67 Progesterone is synthesized
in the brain by neurons and glial cells68,69 and the proges-
terone receptor is expressed by neurons and oligodendro-
cytes.49,66,70–72 Furthermore, steroid-responsive elements
including progesterone receptor binding sites73–75 can be
predicted in PLP1 promoter (data not shown) and daily
progesterone injections upregulate Plp1 mRNA in sciatic
nerves of rats in vivo (Figure S1 available online).37 In
the PNS, the activating effect of progesterone on Schwann
cell differentiation and the transcriptional activation of
myelin genes Pmp22 and Mpz are well known.76,77 The
progesterone receptor antagonists Mifepristone (RU486),
Onapristone (ZK98299), and the newly developed Lonap-
risan (ZK230211), which was used in the present study,
specifically inhibit the effect of the progesterone receptor
on transcriptional activation.51 However, there are no
data on the functional role of progesterone receptor on
Plp1 transcription.
In the present study, we have chosen Lonaprisan
because of its pure progesterone antagonistic activity
without partial agonistic potential such as demonstrated
by Mifepristone.78 Furthermore, Lonaprisan shows a
more favorable safety profile than Onapristone, which
may enable translation of our findings to humans.79
Lonaprisan was shown to cross the blood-brain barrier in
wild-type mice and, in a dose-finding pilot study for
10 days in PMD mice, Lonaprisan daily treatment at
125 mg/kg body weight demonstrated potency to downre-
gulate Plp1 1.8-fold mRNA overexpression to 1.5-fold
expression. Importantly, after 10 weeks of daily Lonaprisan
therapy, Plp1 mRNA overexpression was still reduced to
1.6-fold expression. Because PLP1 is most abundantly ex-
pressed in oligodendrocytes and Plp1 transgenic mice do
not show ectopic PLP1 expression in the CNS,30 the reduc-
tion of Plp1 mRNA overexpression is predominantly
restricted to oligodendrocytes. We have not quantified
PLP1 protein because Plp1 dosage interferes with myelina-
tion itself.30 Therefore, any quantification of PLP1 proteins
of PMD mice may yield a paradoxic result, because less
(rather than more) PLP1 is detected, with PLP1 serving
as a marker for myelin. Consequently, our attempts offter Lonaprisan therapy, indicating changes in cell cycle regulation
ates corpus callosum, ns indicates not significant, *p < 0.05, **p <
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pharmacologically reducing Plp1 transcription and res-
cuing myelination in the mouse model would conse-
quently lead to more myelin and more myelin protein
(including PLP1).
Lonaprisan therapy significantly prevented the loss of
myelinated axons and improved the motor phenotype in
PMD mice by approximately 50% toward wild-type level
as shown with the grid test analysis. Applying a second
phenotype measurement, the clinical score data revealed
a higher percentage of PMD mice showing solely ataxic
gait or even healthy condition after long-term therapy
with Lonaprisan. Body weight loss as a sign for unspecific
side effects was not observed in Lonaprisan-treated mice.
However, Lonaprisan treatment did not show an effect
on the number of unmyelinated axons nor on myelin
sheath thickness. Importantly, Plp1 mRNA levels corre-
lated inversely with the number of myelinated axons and
with the phenotype of PMD mice. Further, myelinated
axon numbers correlated with the clinical phenotype.
These observations confirm the importance of tight Plp1
regulation and support the concept that the reduction of
toxic Plp1mRNA overexpression poses the key mechanism
for the progesterone antagonistic effect. However, it is not
known to what degree the progesterone receptor contrib-
utes to Plp1 mRNA expression.
In a randomized phase II study to investigate the effi-
cacy, safety, and tolerability of Lonaprisan as second-line
endocrine therapy for postmenopausal women with hor-
mone receptor-positive metastatic breast cancer, maxi-
mum oral dosage of 100 mg was applied (ClinicalTrials.gov
identifier NCT00555919). Therefore, when translating the
current findings to human use, careful dose finding target-
ing Plp1 expression in individuals suffering from PMD is
necessary.
PMDmice suffer from a lymphocyte infiltration into the
CNS,36,80 microglia activation, and astrogliosis as well as
described features.30,32,34,35 Lonaprisan therapy signifi-
cantly decreased the number of lymphocytes present in
the CNS, suggesting that there is reduced inflammation
after long-term treatment with the progesterone antago-
nist. Because loss of progesterone receptor function mu-
tants show proinflammatory effects,81 we interpret the
reduced inflammation as secondary effect resulting from
improved PMD pathology. Further effects of the long-
term therapy with Lonaprisan included the prevention of
OLIG-2-stained oligodendrocyte lineage cells and the
reduction of MAC-3-stained microglia and GFAP-stained
astrogliosis.
In order to address the mechanism by which Lonaprisan
treatment can prevent axonal loss, we performed microar-
ray analysis and applied the gene set enrichment analysis
(GSEA). We found a significant downregulation of genes
involved in apoptosis and validated this finding by quanti-
tative RT-PCR at the level of single animals (n ¼ 8–11) for
three highly downregulated apoptotic genes: Jun, Casp7,
and Bax. At the transcriptional level, the expression of all
three genes was upregulated in PMD mice and downregu-542 The American Journal of Human Genetics 94, 533–546, April 3, 2lated after Lonaprisan therapy. By immunohistochemistry,
PMD pathology was directly associated with higher
apoptosis and proliferation marker expression when
compared to wild-type littermates (BAX82 and Ki67,83
respectively). These observations are in line with an in-
crease in apoptotic oligodendrocytes in PMD mice.32,35
Importantly, Lonaprisan therapy significantly reduced
the number of cells overexpressing these apoptosis and
proliferation markers. Furthermore, cell counts for
c-MYC, a key regulator of cell cycle with proapoptotic
and proproliferative actions,84 showed less c-MYC expres-
sion after Lonaprisan treatment.
Saher et al. recently reported a therapeutic strategy with
high-cholesterol diet in PMDmice.28 This effect ismediated
by the amelioration of intracellular PLP1 accumulation and
increased PLP1 incorporation into myelin membranes that
was accompanied by an upregulation of cholesterol-
synthesizing enzymes (Hmgcr and Fdft1 mRNA) without
regulatory effects on Plp1 mRNA overexpression itself. In
contrast, Lonaprisan in PMD mice did not affect choles-
terol-synthesizing-enzyme expression of Hmgcr, Fdft1,
Mvd, or Lss mRNA (Figures S2A–S2D). Because cholesterol
and Lonaprisan experimental therapies act independently,
the combination may lead to synergistic effects.
Further more, a strong argument for therapeutic regula-
tion of toxic overexpression of myelin proteins in the CNS
is derived from a former therapy trial performed in a trans-
genic rat model for the most common inherited neuropa-
thy, Charcot-Marie-Tooth disease (‘‘CMT1A’’ rats).37,85,86
CMT1A is caused by an intrachromosomal duplication
on chromosomal region 17p11.2 that leads to an increased
gene dosage of the peripheral myelin protein of 22 kDa and
consecutive demyelination of peripheral nerve axons.87
PMP22 is a small hydrophobic tetraspan protein expressed
in myelinating glia of the PNS and shows a similar
structure to PLP1. Daily administration of the pure proges-
terone antagonist Onapristone reduced Pmp22 overexpres-
sion, ameliorated axonal loss, and improved the clinical
phenotype in Pmp22 transgenic CMT rats.37,88 In contrast
to the correlations in the present study, CMT rats did not
demonstrate stringent correlations of Pmp22 mRNA
expression, axonal numbers, and the clinical phenotype
upon antiprogesterone treatment, which may be ex-
plained by themissing consensus regions for the progester-
one receptor in the Pmp22 promoter region. However, the
observation of preserved axonal loss without any effects on
myelin sheath thickness in the present study is consistent
with the former progesterone therapy trial in CMT rats. In
that study, we hypothesized that Pmp22 overexpression
was reduced to a degree at which the axonal support func-
tion of Schwann cells was better maintained thanmyelina-
tion.89 We note that Plp1 loss-of-function mutants show
no crude myelin abnormalities but demonstrate axonal
pathology,5,22 implying that PLP1 is responsible for axonal
support rather than myelination in the CNS. Because
we do not assume that overexpression linearly contributes
to PMD pathology and that oligodendrocytes tolerate014
increasing Plp1 mRNA levels only to a certain degree, the
initial correction toward wild-type level may be considered
as most important for axonal support.
In summary, we demonstrate proof of principle that
lowering toxic Plp1 overexpression via a progesterone
antagonist ameliorates axonal loss and the disease pheno-
type in Plp1 transgenic mice.Supplemental Data
Supplemental Data include two figures and can be found with this
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